Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.60
-0.09 (-1.58%)
May 28, 2025, 4:00 PM - Market closed

Coya Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
3.693.556---
Revenue Growth (YoY)
-39.88%-40.79%----
Cost of Revenue
11.8711.875.54.41--
Gross Profit
-8.18-8.310.5-4.41--
Selling, General & Admin
9.168.897.834.852.310.67
Research & Development
2.08---2.540.04
Operating Expenses
11.268.917.864.874.870.7
Operating Income
-19.44-17.22-7.36-9.29-4.87-0.7
Interest Expense
------0.06
Interest & Investment Income
1.651.650.64---
Other Non Operating Income (Expenses)
-0.06---2.43-0.020
EBT Excluding Unusual Items
-17.86-15.58-6.72-11.72-4.89-0.76
Pretax Income
-17.86-15.6-7.26-12.24-4.89-1.1
Income Tax Expense
-0.72-0.720.72---
Net Income
-17.14-14.88-7.99-12.24-4.89-1.1
Net Income to Common
-17.14-14.88-7.99-12.24-4.89-1.1
Shares Outstanding (Basic)
161510332
Shares Outstanding (Diluted)
161510332
Shares Change (YoY)
39.27%49.93%292.40%0.01%40.88%-
EPS (Basic)
-1.08-0.98-0.79-4.73-1.89-0.60
EPS (Diluted)
-1.09-0.98-0.79-4.73-1.89-0.60
Free Cash Flow
-15.26-10.29-11.19-7.24-4.04-0.59
Free Cash Flow Per Share
-0.97-0.68-1.10-2.79-1.56-0.32
Gross Margin
-221.99%-233.86%8.34%---
Operating Margin
-527.63%-484.65%-122.62%---
Profit Margin
-465.00%-418.70%-133.08%---
Free Cash Flow Margin
-414.18%-289.50%-186.41%---
EBITDA
-19.42-17.2-7.33-9.26-4.85-
EBITDA Margin
---122.17%---
D&A For EBITDA
0.030.030.030.030.02-
EBIT
-19.44-17.22-7.36-9.29-4.87-0.7
EBIT Margin
---122.62%---
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q